NO324064B1 - Farmasoytisk preparat omfattende vWF-propeptid samt fremgangsmate for fremstilling og anvendelse derav - Google Patents

Farmasoytisk preparat omfattende vWF-propeptid samt fremgangsmate for fremstilling og anvendelse derav Download PDF

Info

Publication number: NO324064B1
Authority: NO; Norway
Prior art keywords: vwf; pro; propeptide; preparation; pharmaceutical
Prior art date: 1997-05-28

Application number

NO19995843A

Other languages

English (en)

Norwegian (no)

Other versions

NO995843L (no

NO995843D0 (no

Inventor

Hans-Peter Schwarz

Peter Turecek

Katalin Varadi

Hendrik Coenraad Hemker

Suzette Lucette Beguin

Original Assignee

Baxter Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-28

Filing date

1999-11-29

Publication date

2007-08-06

1999-11-29 Application filed by Baxter Ag filed Critical Baxter Ag

1999-11-29 Publication of NO995843D0 publication Critical patent/NO995843D0/no

2000-01-27 Publication of NO995843L publication Critical patent/NO995843L/no

2007-08-06 Publication of NO324064B1 publication Critical patent/NO324064B1/no

Links

238000002360 preparation method Methods 0.000 title claims abstract description 56
238000000034 method Methods 0.000 title claims description 19
239000008194 pharmaceutical composition Substances 0.000 title claims description 6
239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 27
238000004519 manufacturing process Methods 0.000 claims abstract description 7
208000015294 blood coagulation disease Diseases 0.000 claims abstract description 4
108010047303 von Willebrand Factor Proteins 0.000 claims description 185
102100036537 von Willebrand factor Human genes 0.000 claims description 184
229960001134 von willebrand factor Drugs 0.000 claims description 184
230000000694 effects Effects 0.000 claims description 23
241000700605 Viruses Species 0.000 claims description 12
238000003776 cleavage reaction Methods 0.000 claims description 12
230000007017 scission Effects 0.000 claims description 12
239000000463 material Substances 0.000 claims description 11
108090000623 proteins and genes Proteins 0.000 claims description 11
102000004169 proteins and genes Human genes 0.000 claims description 11
229920001436 collagen Polymers 0.000 claims description 8
102000008186 Collagen Human genes 0.000 claims description 7
108010035532 Collagen Proteins 0.000 claims description 7
230000023555 blood coagulation Effects 0.000 claims description 7
229960000182 blood factors Drugs 0.000 claims description 7
230000002779 inactivation Effects 0.000 claims description 7
239000003112 inhibitor Substances 0.000 claims description 6
230000035772 mutation Effects 0.000 claims description 6
208000031220 Hemophilia Diseases 0.000 claims description 5
208000009292 Hemophilia A Diseases 0.000 claims description 5
230000023597 hemostasis Effects 0.000 claims description 5
108010054218 Factor VIII Proteins 0.000 claims description 4
102000001690 Factor VIII Human genes 0.000 claims description 4
108010018823 anti-inhibitor coagulant complex Proteins 0.000 claims description 4
229940105776 factor viii inhibitor bypassing activity Drugs 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 4
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
108020004511 Recombinant DNA Proteins 0.000 claims description 3
238000001042 affinity chromatography Methods 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
238000005516 engineering process Methods 0.000 claims description 3
229960000301 factor viii Drugs 0.000 claims description 3
229960002897 heparin Drugs 0.000 claims description 3
229920000669 heparin Polymers 0.000 claims description 3
239000003446 ligand Substances 0.000 claims description 3
201000003542 Factor VIII deficiency Diseases 0.000 claims description 2
229940124135 Factor VIII inhibitor Drugs 0.000 claims description 2
108010061932 Factor VIIIa Proteins 0.000 claims description 2
102000009123 Fibrin Human genes 0.000 claims description 2
108010073385 Fibrin Proteins 0.000 claims description 2
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 2
108010049003 Fibrinogen Proteins 0.000 claims description 2
102000008946 Fibrinogen Human genes 0.000 claims description 2
208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims description 2
201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims description 2
206010019617 Henoch-Schonlein purpura Diseases 0.000 claims description 2
208000031814 IgA Vasculitis Diseases 0.000 claims description 2
208000009567 Neonatal Alloimmune Thrombocytopenia Diseases 0.000 claims description 2
102000015795 Platelet Membrane Glycoproteins Human genes 0.000 claims description 2
108010010336 Platelet Membrane Glycoproteins Proteins 0.000 claims description 2
201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims description 2
239000012876 carrier material Substances 0.000 claims description 2
238000004113 cell culture Methods 0.000 claims description 2
238000004587 chromatography analysis Methods 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
229950003499 fibrin Drugs 0.000 claims description 2
229940012952 fibrinogen Drugs 0.000 claims description 2
208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 2
208000010125 myocardial infarction Diseases 0.000 claims description 2
208000030372 neonatal thrombocytopenia Diseases 0.000 claims description 2
150000003904 phospholipids Chemical class 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
238000000926 separation method Methods 0.000 claims description 2
238000001356 surgical procedure Methods 0.000 claims description 2
230000009931 harmful effect Effects 0.000 claims 1
201000011461 pre-eclampsia Diseases 0.000 claims 1
210000002381 plasma Anatomy 0.000 description 27
108090000190 Thrombin Proteins 0.000 description 21
229960004072 thrombin Drugs 0.000 description 21
210000001772 blood platelet Anatomy 0.000 description 15
239000000427 antigen Substances 0.000 description 10
102000036639 antigens Human genes 0.000 description 10
108091007433 antigens Proteins 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 7
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
238000012545 processing Methods 0.000 description 6
239000003146 anticoagulant agent Substances 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
239000000126 substance Substances 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
208000032843 Hemorrhage Diseases 0.000 description 4
208000027276 Von Willebrand disease Diseases 0.000 description 4
208000034158 bleeding Diseases 0.000 description 4
231100000319 bleeding Toxicity 0.000 description 4
230000000740 bleeding effect Effects 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
238000001802 infusion Methods 0.000 description 4
208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
208000007536 Thrombosis Diseases 0.000 description 3
230000004913 activation Effects 0.000 description 3
229940127219 anticoagulant drug Drugs 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000002439 hemostatic effect Effects 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
200000000007 Arterial disease Diseases 0.000 description 2
206010003178 Arterial thrombosis Diseases 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
102000012422 Collagen Type I Human genes 0.000 description 2
108010022452 Collagen Type I Proteins 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
102100035233 Furin Human genes 0.000 description 2
108090001126 Furin Proteins 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
102000007625 Hirudins Human genes 0.000 description 2
108010007267 Hirudins Proteins 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
208000035868 Vascular inflammations Diseases 0.000 description 2
230000002429 anti-coagulating effect Effects 0.000 description 2
230000002785 anti-thrombosis Effects 0.000 description 2
239000000729 antidote Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000015271 coagulation Effects 0.000 description 2
238000005345 coagulation Methods 0.000 description 2
230000002950 deficient Effects 0.000 description 2
239000003527 fibrinolytic agent Substances 0.000 description 2
229940006607 hirudin Drugs 0.000 description 2
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
102000006495 integrins Human genes 0.000 description 2
108010044426 integrins Proteins 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000006337 proteolytic cleavage Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
230000001732 thrombotic effect Effects 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
206010067484 Adverse reaction Diseases 0.000 description 1
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
108090000604 Hydrolases Proteins 0.000 description 1
102000004157 Hydrolases Human genes 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102000008300 Mutant Proteins Human genes 0.000 description 1
108010021466 Mutant Proteins Proteins 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
102000002067 Protein Subunits Human genes 0.000 description 1
108010001267 Protein Subunits Proteins 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
206010047112 Vasculitides Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000001567 anti-fibrinolytic effect Effects 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
108010083526 asialo-von Willebrand Factor Proteins 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
229940019700 blood coagulation factors Drugs 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000008859 change Effects 0.000 description 1
230000003196 chaotropic effect Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
229960005188 collagen Drugs 0.000 description 1
235000021277 colostrum Nutrition 0.000 description 1
210000003022 colostrum Anatomy 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000000539 dimer Substances 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
102000057593 human F8 Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
229940124280 l-arginine Drugs 0.000 description 1
239000002523 lectin Substances 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000008267 milk Substances 0.000 description 1
238000001728 nano-filtration Methods 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
238000000053 physical method Methods 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002947 procoagulating effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
229940047431 recombinate Drugs 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000007787 solid Substances 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
101800001769 von Willebrand antigen 2 Proteins 0.000 description 1
102400000842 von Willebrand antigen 2 Human genes 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO19995843A 1997-05-28 1999-11-29 Farmasoytisk preparat omfattende vWF-propeptid samt fremgangsmate for fremstilling og anvendelse derav NO324064B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AT0091797A AT405485B (de)	1997-05-28	1997-05-28	Eine das vwf-propeptid enthaltende pharmazeutische präparation
PCT/EP1998/003090 WO1998053848A1 (en)	1997-05-28	1998-05-26	PHARMACEUTICAL PREPARATION COMPRISING vWF PROPEPTIDE

Publications (3)

Publication Number	Publication Date
NO995843D0 NO995843D0 (no)	1999-11-29
NO995843L NO995843L (no)	2000-01-27
NO324064B1 true NO324064B1 (no)	2007-08-06

Family

ID=3502803

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19995843A NO324064B1 (no)	1997-05-28	1999-11-29	Farmasoytisk preparat omfattende vWF-propeptid samt fremgangsmate for fremstilling og anvendelse derav

Country Status (10)

Country	Link
US (2)	US7005502B1 (ja)
EP (1)	EP0977584B1 (ja)
JP (1)	JP4335978B2 (ja)
AT (2)	AT405485B (ja)
AU (1)	AU744643B2 (ja)
CA (1)	CA2288737A1 (ja)
DE (1)	DE69802918T2 (ja)
ES (1)	ES2168766T3 (ja)
NO (1)	NO324064B1 (ja)
WO (1)	WO1998053848A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4663837B2 (ja) *	1999-12-24	2011-04-06	一般財団法人化学及血清療法研究所	第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
EP1240900B1 (en) *	1999-12-24	2009-05-06	Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute	Factor viii or von willebrand factor for the treatment of hemorrhagic diseases associating thrombopathy
BRPI0519562A2 (pt)	2004-12-27	2009-01-27	Baxter Int	construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea
JP2009532351A (ja)	2006-03-31	2009-09-10	バクスター・インターナショナル・インコーポレイテッド	ペグ化第ｖｉｉｉ因子
US7645860B2 (en)	2006-03-31	2010-01-12	Baxter Healthcare S.A.	Factor VIII polymer conjugates
US20090192076A1 (en)	2007-12-28	2009-07-30	Baxter International Inc.	Recombinant vwf formulations
US11197916B2 (en)	2007-12-28	2021-12-14	Takeda Pharmaceutical Company Limited	Lyophilized recombinant VWF formulations
ES2298096B1 (es) *	2008-01-08	2009-01-01	Grifols, S.A.	Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
CN102387784B (zh) *	2008-10-21	2014-04-02	巴克斯特国际公司	冻干的重组vwf配方
EP3495488A1 (en) *	2008-10-27	2019-06-12	Baxalta GmbH	Models of thrombotic thrombocytopenic purpura and methods of use thereof
MX2012002129A (es)	2009-08-20	2012-06-08	Baxter Int	Purificacion del factor de von willebrand (vwf) para remocion incrementada de virus envueltos sin lipido.
US20110150843A1 (en) *	2009-10-30	2011-06-23	National Institute Of Immunology	Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US9700486B2 (en)	2013-04-24	2017-07-11	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
KR102104843B1 (ko)	2015-10-02	2020-04-28	에이에스엠엘 네델란즈 비.브이.	계측 방법 및 장치, 컴퓨터 프로그램 및 리소그래피 시스템
KR20200037251A (ko)	2017-07-07	2020-04-08	박스알타 인코퍼레이티드	재조합 vwf의 투여에 의해 대기 수술을 받은 중증 폰 빌레브란트 병을 가지고 있는 환자의 치료
CN111436193A (zh)	2017-07-07	2020-07-21	百深公司	通过施用重组vwf来治疗患有严重冯维勒布兰德病的患者中的胃肠道出血
MX2020009788A (es)	2018-03-21	2020-12-09	Takeda Pharmaceuticals Co	Separación de factor de von willebrand (vwf) y propéptido de factor de von willebrand (vwf) por métodos cromatográficos.
EP3917557A1 (en)	2019-02-01	2021-12-08	Takeda Pharmaceutical Company Limited	Methods of prophylactic treatment using recombinant vwf (rvwf)
WO2021050718A1 (en)	2019-09-11	2021-03-18	Baxalta Incorporated	Methods of treatment related to complexes of von willebrand factor and complement c1q
TW202134266A (zh)	2020-02-04	2021-09-16	日商武田藥品工業股份有限公司	藉由投予重組vwf治療患有嚴重馮威里氏病之患者之經血過多

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT350726B (de)	1976-08-30	1979-06-11	Immuno Ag	Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma
AT368883B (de)	1980-07-22	1982-11-25	Immuno Ag	Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4540573A (en)	1983-07-14	1985-09-10	New York Blood Center, Inc.	Undenatured virus-free biologically active protein derivatives
AT378005B (de)	1983-08-20	1985-06-10	Linde Ag	Verfahren zum desoxidieren von metallschmelzen
AT389815B (de)	1984-03-09	1990-02-12	Immuno Ag	Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US5198349A (en) *	1986-01-03	1993-03-30	Genetics Institute, Inc.	Method for producing factor VIII:C and analogs
AT390560B (de)	1986-05-30	1990-05-25	Immuno Ag	Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
US5849536A (en) *	1990-03-02	1998-12-15	Bio-Technology General Corp.	Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same
FR2673632A1 (fr) *	1991-03-08	1992-09-11	Lille Transfusion Sanguine	Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
AT402891B (de)	1991-06-20	1997-09-25	Immuno Ag	Verfahren zur herstellung eines inaktivierten blutproduktes
AT398079B (de)	1991-11-04	1994-09-26	Immuno Ag	Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung
AU6653094A (en)	1992-12-16	1994-07-04	Immuno Aktiengesellschaft	Process for preparing a virus-safe biological composition
AT402788B (de)	1993-08-03	1997-08-25	Immuno Ag	Virussichere blutgerinnungsfaktor xiii-präparation
JPH07330797A (ja) *	1994-05-31	1995-12-19	Sumitomo Metal Ind Ltd	新規細胞接着活性ペプチド
DE4437544A1 (de) *	1994-10-20	1996-04-25	Behringwerke Ag	Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
AT404359B (de)	1996-04-29	1998-11-25	Immuno Ag	Gereinigte multimerase
US6068838A (en)	1996-04-29	2000-05-30	Baxter Aktiengesellschaft	Purified multimerase
AT404554B (de)	1996-04-29	1998-12-28	Immuno Ag	Pharmazeutische präparation

1997
- 1997-05-28 AT AT0091797A patent/AT405485B/de not_active IP Right Cessation
1998
- 1998-05-26 DE DE69802918T patent/DE69802918T2/de not_active Expired - Lifetime
- 1998-05-26 US US09/424,498 patent/US7005502B1/en not_active Expired - Lifetime
- 1998-05-26 AT AT98929378T patent/ATE210455T1/de active
- 1998-05-26 ES ES98929378T patent/ES2168766T3/es not_active Expired - Lifetime
- 1998-05-26 EP EP98929378A patent/EP0977584B1/en not_active Expired - Lifetime
- 1998-05-26 JP JP50022099A patent/JP4335978B2/ja not_active Expired - Lifetime
- 1998-05-26 CA CA002288737A patent/CA2288737A1/en not_active Abandoned
- 1998-05-26 WO PCT/EP1998/003090 patent/WO1998053848A1/en active IP Right Grant
- 1998-05-26 AU AU79156/98A patent/AU744643B2/en not_active Expired
1999
- 1999-11-29 NO NO19995843A patent/NO324064B1/no not_active IP Right Cessation
2005
- 2005-09-01 US US11/218,406 patent/US7557188B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69802918D1 (de)	2002-01-24
US7005502B1 (en)	2006-02-28
AU744643B2 (en)	2002-02-28
JP4335978B2 (ja)	2009-09-30
US20060003921A1 (en)	2006-01-05
AU7915698A (en)	1998-12-30
JP2001527579A (ja)	2001-12-25
NO995843L (no)	2000-01-27
DE69802918T2 (de)	2003-04-10
WO1998053848A1 (en)	1998-12-03
CA2288737A1 (en)	1998-12-03
ATE210455T1 (de)	2001-12-15
EP0977584A1 (en)	2000-02-09
ATA91797A (de)	1999-01-15
AT405485B (de)	1999-08-25
EP0977584B1 (en)	2001-12-12
ES2168766T3 (es)	2002-06-16
US7557188B2 (en)	2009-07-07
NO995843D0 (no)	1999-11-29

Publication	Publication Date	Title
NO324064B1 (no)	2007-08-06	Farmasoytisk preparat omfattende vWF-propeptid samt fremgangsmate for fremstilling og anvendelse derav
US5877152A (en)	1999-03-02	Method for isolation of highly pure von Willebrand Factor
Koedam et al.	1988	Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor.
KR100303872B1 (ko)	2001-11-22	응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법
EP0719154B1 (en)	2001-10-31	Activated factor viii as a therapeutic agent and method of treating factor viii deficiency
JPH09221432A (ja)	1997-08-26	フォンビルブラント因子を含む医薬調製物
US5484890A (en)	1996-01-16	Antihemophilic factor stabilization
EP0907724B1 (en)	2007-03-21	Von willebrand factor multimerase
JP2005511038A (ja)	2005-04-28	第ｖｉｉｉ因子ｃ２ドメインのバリアント
US20140193441A1 (en)	2014-07-10	Method of Administering Porcine B-domainless fVIII
Mitchell et al.	1987	Cleavage of protein S by a platelet membrane protease.
Seligsohn et al.	2001	Inherited deficiencies of coagulation factors II, V, VII, XI and XIII and the combined deficiencies of Factors V and VIII and of the Vitamin K dependent factors
CA2301514A1 (en)	1999-03-04	Dried biologically or therapeutically active preparations
US5091363A (en)	1992-02-25	Agent for the therapy of factor viii-resistant hemophilia a, and a process for the preparation thereof
US20240189398A1 (en)	2024-06-13	Liquid composition comprising factor viii or factor viii/von willebrand factor complex
Turecek et al.	2013	Factor eight inhibitor bypassing activity
Chung et al.	1990	The antithrombotic properties of human prothrombin fragment 1.2 in mice
AU8723198A (en)	1999-03-16	Dried biologically or therapeutically active preparations

Legal Events

Date	Code	Title	Description
2015-10-26	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: BAXALTA INCORPORATED, CH
2018-06-11	MK1K	Patent expired